\-\ Texto\\:\\ \ \(0\)\
\-\ negative\\ clinical\\ breast\\ exam\\ by\\ experienced\\ surgeon\\,\\ negative\\ screening\\ mammography\\.\\ genetics\\ testing\\ revealed\\ brca\\-1\\ positivity\\.\ \(0\)\
\-\ patient\\ will\\ undergo\\ lymphoscintigraphy\\ for\\ sentinal\\ node\\ biopsy\\.\\ if\\ no\\ metastases\\,\\ she\\ will\\ likely\\ opt\\ for\\ breast\\ conservation\\ therapy\\ to\\ include\\ lumpectomy\\ and\\ radiation\\.\\ \\ she\\ is\\ considering\\ the\\ option\\ of\\ bilateral\\ mastectomy\\.\\ \\ she\\ will\\ require\\ continued\\ close\\ monitoring\\ for\\ development\\ of\\ additional\\ disease\\.\ \(0\)\
\-\ initial\\ screening\\ two\\ view\\ mammogram\\ was\\ negative\\ for\\ suspicious\\ calcifications\\ or\\ mass\\.\\ \\ the\\ brest\\ tissue\\ was\\ heterogenously\\ dense\\.\ \(0\)\
\-\ patient\\ underwent\\ routine\\ screeing\\ breast\\ mr\\ which\\ demonstrates\\ a\\ small\\ enhancing\\ mass\\ within\\ the\\ mid\\ right\\ breast\\,\\ 12\\:00\\ position\\.\\ \\ there\\ is\\ minimal\\ associated\\ t2\\ hyperintensity\\,\\ but\\ this\\ involves\\ more\\ the\\ periphery\\ of\\ the\\ lesion\\,\\ rather\\ than\\ the\\ substance\\ of\\ the\\ lesion\\ itslef\\.\\ \\ no\\ other\\ discordant\\ foci\\ of\\ abnormal\\ enhancement\\ were\\ present\\ within\\ either\\ breast\\.\ \(0\)\
\-\ the\\ patient\\ was\\ recalled\\ for\\ subsequent\\ right\\ breast\\ ultrasound\\.\\ \\ this\\ demonstrates\\ an\\ angulated\\,\\ hypoechoic\\ 5mm\\ mass\\ in\\ at\\ the\\ 12\\:00\\ position\\,\\ zone\\ 1a\\.\ \(0\)\
\-\ subsequent\\ ultrasound\\-guided\\ 14ga\\ core\\ biopsy\\ was\\ performed\\.\ \(0\)\
\-\ infiltrating\\ ductal\\ carcinoma\ \(11\)\
\-\ atypical\\ fibroadenoma\ \(0\)\
\-\ ductal\\ carcinoma\\ in\\ situ\ \(4\)\
\-\ infiltrating\\ carcinoma\ \(0\)\
\-\ atypical\\ lymph\\ node\ \(0\)\
\-\ atypical\\ papilloma\ \(0\)\
\-\ granular\\ cell\\ tumor\ \(4\)\
\-\ 32\\ year\\-old\\ female\\,\\ asymptomatic\\ with\\ respect\\ to\\ the\\ breasts\\.\\ \\ \\ patient\\ has\\ a\\ mother\\ and\\ sister\\ with\\ breast\\ cancer\\ before\\ age\\ 45\\.\\ \\ she\\ is\\ 10\\ months\\ postpartum\\,\\ is\\ no\\ longer\\ lactating\\,\\ but\\ is\\ trying\\ to\\ get\\ pregnant\\.\ \(0\)\
\-\ the\\ issue\\ of\\ screening\\ high\\ risk\\ patients\\ with\\ breast\\ mr\\ has\\ been\\ discussed\\ for\\ several\\ years\\.\\ \\ it\\ has\\ taken\\ some\\ time\\ for\\ vendors\\ to\\ develop\\ the\\ software\\ necessary\\ to\\ accurately\\ and\\ efficiently\\ use\\ existing\\ mr\\ technology\\ for\\ a\\ screening\\ population\\.\\ \\ mr\\ utility\\ has\\ been\\ extensively\\ used\\ for\\ problem\\-solving\\ and\\ for\\ evaluation\\ of\\ the\\ patient\\ with\\ impants\\.\\ \ \(0\)\
\-\ the\\ exquisite\\ contrast\\ sensitivity\\ of\\ mr\\ is\\ balanced\\ in\\ the\\ high\\-risk\\ patient\\ by\\ somewhat\\ decreased\\ specificity\\;\\ many\\ things\\ other\\ than\\ cancer\\ enhance\\,\\ but\\ benign\\ entities\\ often\\ have\\ an\\ intrinsic\\ high\\ t2\\ signal\\ whereas\\ breast\\ cancer\\ does\\ not\\.\ \(0\)\
\-\ sensitivity\\ has\\ been\\ greatly\\ improved\\ with\\ the\\ use\\ of\\ dynamic\\ contrast\\-enhancement\\,\\ and\\ the\\ addition\\ of\\ software\\ tools\\ allowing\\ the\\ creation\\ of\\ a\\ graphical\\ depiction\\ of\\ contrast\\ kinetics\\ within\\ a\\ specified\\ region\\ of\\ interest\\.\\ \\ given\\ that\\ the\\ region\\ is\\ selected\\ appropriately\\,\\ breast\\ cancer\\ tissue\\ will\\ typically\\ exhibit\\ an\\ early\\ wash\\-in\\,\\ and\\ a\\ rapid\\ wash\\-out\\ of\\ contrast\\ enhancement\\.\\ \\ in\\ contradistinction\\,\\ beningn\\ tissue\\ will\\ demonstrate\\ a\\ progressive\\ increase\\ in\\ enhancement\\ or\\ alternatively\\ a\\ plateau\\.\\ \ \(0\)\
\-\ software\\ refinements\\ continue\\ to\\ be\\ made\\ in\\ order\\ to\\ hopefully\\ better\\ define\\ the\\ specific\\ region\\ of\\ interest\\ and\\ therefore\\ yield\\ the\\ best\\ curve\\.\ \(0\)\
\-\ at\\ the\\ time\\ this\\ case\\ was\\ performed\\,\\ the\\ combination\\ fo\\ software\\ and\\ hardware\\ technology\\ necessary\\ to\\ perform\\ adequate\\ screening\\ mr\\ had\\ only\\ been\\ available\\ for\\ approximately\\ 2\\ months\\.\\ \\ this\\ patient\\'s\\ cancer\\ was\\ only\\ detectable\\ initially\\ through\\ this\\ modality\\.\\ \\ the\\ mammogram\\ was\\,\\ even\\ retrospectively\\,\\ negative\\,\\ and\\ there\\ was\\ no\\ palpable\\ abnormality\\ for\\ which\\ to\\ justify\\ an\\ ultrasound\\ \\(although\\ the\\ lesion\\ was\\ in\\ fact\\ visible\\ under\\ ultrasound\\)\\.\\ \\ this\\ cancer\\ almost\\ certainly\\ would\\ have\\ not\\ been\\ found\\ until\\ it\\ was\\ at\\ a\\ much\\ more\\ advanced\\ state\\,\\ and\\ this\\ patient\\'s\\ life\\ may\\ have\\ just\\ been\\ saved\\-\\-\\ a\\ feat\\ that\\ would\\ have\\ likely\\ not\\ been\\ possible\\ just\\ a\\ few\\ months\\ ago\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ breast\\:\\ 0\\.29231763691799373\ \(0\)\
\-\ software\\:\\ 0\\.23163944856397314\ \(0\)\
\-\ the\\:\\ 0\\.20080656360779442\ \(0\)\
\-\ been\\:\\ 0\\.16416973083722813\ \(0\)\
\-\ screening\\:\\ 0\\.16350234954055642\ \(0\)\
\-\ cancer\\:\\ 0\\.16087468428943885\ \(0\)\
\-\ mr\\:\\ 0\\.15627958525851793\ \(0\)\
\-\ for\\:\\ 0\\.14641052856422096\ \(0\)\
\-\ was\\:\\ 0\\.1402914625736989\ \(0\)\
\-\ will\\:\\ 0\\.12954486883097607\ \(0\)\
\-\ of\\:\\ 0\\.11816487090985893\ \(0\)\
\-\ technology\\:\\ 0\\.10918626434184579\ \(0\)\
\-\ patient\\:\\ 0\\.10474255089719677\ \(0\)\
\-\ interest\\:\\ 0\\.1003143108060918\ \(0\)\
\-\ negative\\:\\ 0\\.09968553004882465\ \(0\)\
\-\ ultrasound\\:\\ 0\\.09931927672148894\ \(0\)\
\-\ atypical\\:\\ 0\\.09907493541930139\ \(0\)\
\-\ this\\:\\ 0\\.09682557380124227\ \(0\)\
\-\ she\\:\\ 0\\.09585055133904748\ \(0\)\
\-\ enhancement\\:\\ 0\\.09267951764941544\ \(0\)\
\-\ has\\:\\ 0\\.09193577035825798\ \(0\)\
\-\ to\\:\\ 0\\.09057226500564039\ \(0\)\
\-\ and\\:\\ 0\\.08318131886687584\ \(0\)\
\-\ sensitivity\\:\\ 0\\.08172239764450388\ \(0\)\
\-\ have\\:\\ 0\\.08043763539513532\ \(0\)\
\-\ in\\:\\ 0\\.08011241644876821\ \(0\)\
\-\ infiltrating\\:\\ 0\\.07898215041279984\ \(0\)\
\-\ contrast\\:\\ 0\\.07823566238179622\ \(0\)\
\-\ is\\:\\ 0\\.07716807781091899\ \(0\)\
\-\ mammogram\\:\\ 0\\.07686594981649962\ \(0\)\
\-\ carcinoma\\:\\ 0\\.07223554780732111\ \(0\)\
\-\ region\\:\\ 0\\.07223554780732111\ \(0\)\
\-\ ductal\\:\\ 0\\.07084870441738149\ \(0\)\
\-\ months\\:\\ 0\\.07029440018956522\ \(0\)\
\-\ node\\:\\ 0\\.06919932370943\ \(0\)\
\-\ high\\:\\ 0\\.06863432732444147\ \(0\)\
\-\ necessary\\:\\ 0\\.06735368032299749\ \(0\)\
\-\ just\\:\\ 0\\.06440607137016273\ \(0\)\
\-\ opt\\:\\ 0\\.06437595887429273\ \(0\)\
\-\ brest\\:\\ 0\\.06437595887429273\ \(0\)\
\-\ screeing\\:\\ 0\\.06437595887429273\ \(0\)\
\-\ itslef\\:\\ 0\\.06437595887429273\ \(0\)\
\-\ 14ga\\:\\ 0\\.06437595887429273\ \(0\)\
\-\ vendors\\:\\ 0\\.06437595887429273\ \(0\)\
\-\ efficiently\\:\\ 0\\.06437595887429273\ \(0\)\
\-\ impants\\:\\ 0\\.06437595887429273\ \(0\)\
\-\ graphical\\:\\ 0\\.06437595887429273\ \(0\)\
\-\ kinetics\\:\\ 0\\.06437595887429273\ \(0\)\
\-\ beningn\\:\\ 0\\.06437595887429273\ \(0\)\
\-\ refinements\\:\\ 0\\.06437595887429273\ \(0\)\
\-\ hopefully\\:\\ 0\\.06437595887429273\ \(0\)\
\-\ justify\\:\\ 0\\.06437595887429273\ \(0\)\
\-\ feat\\:\\ 0\\.06437595887429273\ \(0\)\
\-\ position\\:\\ 0\\.06418611415612367\ \(0\)\
\-\ tissue\\:\\ 0\\.0633500560883106\ \(0\)\
\-\ use\\:\\ 0\\.061600774235760276\ \(0\)\
\-\ an\\:\\ 0\\.06157298176699256\ \(0\)\
\-\ conservation\\:\\ 0\\.06151466548803028\ \(0\)\
\-\ balanced\\:\\ 0\\.06151466548803028\ \(0\)\
\-\ subsequent\\:\\ 0\\.06094971544863285\ \(0\)\
\-\ but\\:\\ 0\\.059717971318946024\ \(0\)\
\-\ positivity\\:\\ 0\\.05948454552260781\ \(0\)\
\-\ lymphoscintigraphy\\:\\ 0\\.05948454552260781\ \(0\)\
\-\ sentinal\\:\\ 0\\.05948454552260781\ \(0\)\
\-\ creation\\:\\ 0\\.05948454552260781\ \(0\)\
\-\ discordant\\:\\ 0\\.057909862140993286\ \(0\)\
\-\ lactating\\:\\ 0\\.057909862140993286\ \(0\)\
\-\ tools\\:\\ 0\\.057909862140993286\ \(0\)\
\-\ saved\\:\\ 0\\.057909862140993286\ \(0\)\
\-\ lesion\\:\\ 0\\.057896933149331496\ \(0\)\
\-\ risk\\:\\ 0\\.0575253990374372\ \(0\)\
\-\ would\\:\\ 0\\.05699106510704416\ \(0\)\
\-\ angulated\\:\\ 0\\.05662325213634535\ \(0\)\
\-\ retrospectively\\:\\ 0\\.05662325213634535\ \(0\)\
\-\ biopsy\\:\\ 0\\.05643415746523927\ \(0\)\
\-\ within\\:\\ 0\\.05562016013451045\ \(0\)\
\-\ depiction\\:\\ 0\\.05553543887730671\ \(0\)\
\-\ specified\\:\\ 0\\.05553543887730671\ \(0\)\
\-\ contradistinction\\:\\ 0\\.05553543887730671\ \(0\)\
\-\ extensively\\:\\ 0\\.05376195875008289\ \(0\)\
\-\ 1a\\:\\ 0\\.053018448789308364\ \(0\)\
\-\ fo\\:\\ 0\\.053018448789308364\ \(0\)\
\-\ no\\:\\ 0\\.05236142471698851\ \(0\)\
\-\ exquisite\\:\\ 0\\.052345862217334206\ \(0\)\
\-\ heterogenously\\:\\ 0\\.05173183878466043\ \(0\)\
\-\ yield\\:\\ 0\\.05173183878466043\ \(0\)\
\-\ recalled\\:\\ 0\\.051166991981557136\ \(0\)\
\-\ things\\:\\ 0\\.051166991981557136\ \(0\)\
\-\ utility\\:\\ 0\\.05064402552562179\ \(0\)\
\-\ curve\\:\\ 0\\.05064402552562179\ \(0\)\
\-\ only\\:\\ 0\\.05029765142110878\ \(0\)\
\-\ postpartum\\:\\ 0\\.0501571554030459\ \(0\)\
\-\ trying\\:\\ 0\\.0501571554030459\ \(0\)\
\-\ intrinsic\\:\\ 0\\.0501571554030459\ \(0\)\
\-\ alternatively\\:\\ 0\\.0501571554030459\ \(0\)\
\-\ detectable\\:\\ 0\\.0501571554030459\ \(0\)\
\-\ genetics\\:\\ 0\\.049701718819237975\ \(0\)\
\-\ accurately\\:\\ 0\\.049701718819237975\ \(0\)\
\-\ substance\\:\\ 0\\.04887054539839796\ \(0\)\
\-\ certainly\\:\\ 0\\.04887054539839796\ \(0\)\
\-\ granular\\:\\ 0\\.04848900286972997\ \(0\)\
\-\ sister\\:\\ 0\\.04848900286972997\ \(0\)\
\-\ greatly\\:\\ 0\\.04848900286972997\ \(0\)\
\-\ issue\\:\\ 0\\.048127035437623436\ \(0\)\
\-\ entities\\:\\ 0\\.048127035437623436\ \(0\)\
\-\ hardware\\:\\ 0\\.048127035437623436\ \(0\)\
\-\ likely\\:\\ 0\\.048110375182542714\ \(0\)\
\-\ time\\:\\ 0\\.04771989982225052\ \(0\)\
\-\ not\\:\\ 0\\.04767474223807869\ \(0\)\
\-\ performed\\:\\ 0\\.04762957224627826\ \(0\)\
\-\ define\\:\\ 0\\.04684042543297551\ \(0\)\
\-\ lumpectomy\\:\\ 0\\.046552352056008904\ \(0\)\
\-\ exhibit\\:\\ 0\\.046552352056008904\ \(0\)\
\-\ t2\\:\\ 0\\.046319229896621635\ \(0\)\
\-\ existing\\:\\ 0\\.04627557862987221\ \(0\)\
\-\ mass\\:\\ 0\\.046128612288431015\ \(0\)\
\-\ specificity\\:\\ 0\\.0460092520121355\ \(0\)\
\-\ allowing\\:\\ 0\\.04575261217393687\ \(0\)\
\-\ than\\:\\ 0\\.04563844032359473\ \(0\)\
\-\ at\\:\\ 0\\.04561407987560408\ \(0\)\
\-\ dynamic\\:\\ 0\\.04550497912417905\ \(0\)\
\-\ respect\\:\\ 0\\.04526574205136097\ \(0\)\
\-\ situ\\:\\ 0\\.04481030546755305\ \(0\)\
\-\ appropriately\\:\\ 0\\.04438248855808484\ \(0\)\
\-\ more\\:\\ 0\\.044208223675107086\ \(0\)\
\-\ fibroadenoma\\:\\ 0\\.04417792879232233\ \(0\)\
\-\ plateau\\:\\ 0\\.04417792879232233\ \(0\)\
\-\ breasts\\:\\ 0\\.04397913204671305\ \(0\)\
\-\ get\\:\\ 0\\.04378578247836026\ \(0\)\
\-\ considering\\:\\ 0\\.04359758951804505\ \(0\)\
\-\ selected\\:\\ 0\\.043235622085938515\ \(0\)\
\-\ 5mm\\:\\ 0\\.0428913187876744\ \(0\)\
\-\ mastectomy\\:\\ 0\\.04272526835505051\ \(0\)\
\-\ whereas\\:\\ 0\\.04272526835505051\ \(0\)\
\-\ pregnant\\:\\ 0\\.04224934752526151\ \(0\)\
\-\ mammography\\:\\ 0\\.041949012081290586\ \(0\)\
\-\ other\\:\\ 0\\.04180977859284238\ \(0\)\
\-\ perform\\:\\ 0\\.04152119517182237\ \(0\)\
\-\ it\\:\\ 0\\.041211591843879194\ \(0\)\
\-\ longer\\:\\ 0\\.040988352132349824\ \(0\)\
\-\ option\\:\\ 0\\.04061356577249412\ \(0\)\
\-\ periphery\\:\\ 0\\.04061356577249412\ \(0\)\
\-\ state\\:\\ 0\\.04061356577249412\ \(0\)\
\-\ demonstrates\\:\\ 0\\.04044700317650921\ \(0\)\
\-\ core\\:\\ 0\\.04037432869967605\ \(0\)\
\-\ monitoring\\:\\ 0\\.0401429368947982\ \(0\)\
\-\ hyperintensity\\:\\ 0\\.0401429368947982\ \(0\)\
\-\ discussed\\:\\ 0\\.039918892115868125\ \(0\)\
\-\ modality\\:\\ 0\\.039809481896572754\ \(0\)\
\-\ continue\\:\\ 0\\.03949107520639992\ \(0\)\
\-\ with\\:\\ 0\\.03941182479735681\ \(0\)\
\-\ adequate\\:\\ 0\\.03918641705614657\ \(0\)\
\-\ surgeon\\:\\ 0\\.039087718695028126\ \(0\)\
\-\ zone\\:\\ 0\\.038894369126675335\ \(0\)\
\-\ fact\\:\\ 0\\.03861392886866325\ \(0\)\
\-\ experienced\\:\\ 0\\.03825654527418811\ \(0\)\
\-\ population\\:\\ 0\\.038084419233969456\ \(0\)\
\-\ better\\:\\ 0\\.03799990543598948\ \(0\)\
\-\ advanced\\:\\ 0\\.037833855003365585\ \(0\)\
\-\ undergo\\:\\ 0\\.03759188325979621\ \(0\)\
\-\ rapid\\:\\ 0\\.03743505863288618\ \(0\)\
\-\ combination\\:\\ 0\\.03735793417357658\ \(0\)\
\-\ order\\:\\ 0\\.03720616880207652\ \(0\)\
\-\ develop\\:\\ 0\\.037057598729605665\ \(0\)\
\-\ papilloma\\:\\ 0\\.036912092176950836\ \(0\)\
\-\ somewhat\\:\\ 0\\.03662978182013745\ \(0\)\
\-\ which\\:\\ 0\\.03660838546148571\ \(0\)\
\-\ close\\:\\ 0\\.03642522205437494\ \(0\)\
\-\ testing\\:\\ 0\\.0361613850530992\ \(0\)\
\-\ almost\\:\\ 0\\.0361613850530992\ \(0\)\
\-\ enhance\\:\\ 0\\.036033075740412875\ \(0\)\
\-\ suspicious\\:\\ 0\\.03596978547056702\ \(0\)\
\-\ improved\\:\\ 0\\.0357221524208092\ \(0\)\
\-\ rather\\:\\ 0\\.03566157850566236\ \(0\)\
\-\ dense\\:\\ 0\\.035482915347991126\ \(0\)\
\-\ therefore\\:\\ 0\\.035482915347991126\ \(0\)\
\-\ visible\\:\\ 0\\.035482915347991126\ \(0\)\
\-\ involves\\:\\ 0\\.03502747876418321\ \(0\)\
\-\ that\\:\\ 0\\.03493802243645938\ \(0\)\
\-\ much\\:\\ 0\\.03486399304820953\ \(0\)\
\-\ require\\:\\ 0\\.034599661854715\ \(0\)\
\-\ 32\\:\\ 0\\.03449664078731411\ \(0\)\
\-\ hypoechoic\\:\\ 0\\.03439510208895249\ \(0\)\
\-\ mother\\:\\ 0\\.03439510208895249\ \(0\)\
\-\ by\\:\\ 0\\.03418892345320798\ \(0\)\
\-\ few\\:\\ 0\\.03414746903919467\ \(0\)\
\-\ even\\:\\ 0\\.03386134263914355\ \(0\)\
\-\ until\\:\\ 0\\.033497038899190666\ \(0\)\
\-\ under\\:\\ 0\\.03332170521446887\ \(0\)\
\-\ development\\:\\ 0\\.0332785441148726\ \(0\)\
\-\ either\\:\\ 0\\.0332785441148726\ \(0\)\
\-\ life\\:\\ 0\\.03302497847310046\ \(0\)\
\-\ continued\\:\\ 0\\.0329835893938352\ \(0\)\
\-\ foci\\:\\ 0\\.032901532448501775\ \(0\)\
\-\ addition\\:\\ 0\\.032582525918319616\ \(0\)\
\-\ metastases\\:\\ 0\\.03254364528120126\ \(0\)\
\-\ before\\:\\ 0\\.03254364528120126\ \(0\)\
\-\ best\\:\\ 0\\.03239023015685081\ \(0\)\
\-\ increase\\:\\ 0\\.0323147554503916\ \(0\)\
\-\ taken\\:\\ 0\\.032166185377920736\ \(0\)\
\-\ there\\:\\ 0\\.03203440561849226\ \(0\)\
\-\ many\\:\\ 0\\.03173836846845253\ \(0\)\
\-\ initially\\:\\ 0\\.03156749286108651\ \(0\)\
\-\ lymph\\:\\ 0\\.03130241689781217\ \(0\)\
\-\ additional\\:\\ 0\\.031205525428979978\ \(0\)\
\-\ routine\\:\\ 0\\.03117352166534923\ \(0\)\
\-\ made\\:\\ 0\\.03104693858011413\ \(0\)\
\-\ progressive\\:\\ 0\\.030830739069124286\ \(0\)\
\-\ minimal\\:\\ 0\\.0307101067677628\ \(0\)\
\-\ specific\\:\\ 0\\.03050383853624073\ \(0\)\
\-\ used\\:\\ 0\\.030136065412498286\ \(0\)\
\-\ view\\:\\ 0\\.029478530714951767\ \(0\)\
\-\ ago\\:\\ 0\\.029453462064129136\ \(0\)\
\-\ calcifications\\:\\ 0\\.029378786046798208\ \(0\)\
\-\ abnormality\\:\\ 0\\.02928043159356186\ \(0\)\
\-\ early\\:\\ 0\\.029016818614691665\ \(0\)\
\-\ mid\\:\\ 0\\.028969929287458628\ \(0\)\
\-\ palpable\\:\\ 0\\.028280369002465486\ \(0\)\
\-\ typically\\:\\ 0\\.028259209113191883\ \(0\)\
\-\ or\\:\\ 0\\.028007756268130447\ \(0\)\
\-\ does\\:\\ 0\\.02782890697116219\ \(0\)\
\-\ underwent\\:\\ 0\\.02773020861004374\ \(0\)\
\-\ given\\:\\ 0\\.027691112566634694\ \(0\)\
\-\ benign\\:\\ 0\\.027652231929516338\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.027404598879758522\ \(0\)\
\-\ although\\:\\ 0\\.027404598879758522\ \(0\)\
\-\ available\\:\\ 0\\.02731162233339644\ \(0\)\
\-\ possible\\:\\ 0\\.027274772026235815\ \(0\)\
\-\ initial\\:\\ 0\\.02700436278311164\ \(0\)\
\-\ right\\:\\ 0\\.026692168261442425\ \(0\)\
\-\ radiation\\:\\ 0\\.026676079509401592\ \(0\)\
\-\ several\\:\\ 0\\.026411003546127246\ \(0\)\
\-\ revealed\\:\\ 0\\.02639476230124728\ \(0\)\
\-\ often\\:\\ 0\\.026266160696062652\ \(0\)\
\-\ found\\:\\ 0\\.026046597543086317\ \(0\)\
\-\ approximately\\:\\ 0\\.025685402233939728\ \(0\)\
\-\ clinical\\:\\ 0\\.02551150880797115\ \(0\)\
\-\ some\\:\\ 0\\.025327837516618042\ \(0\)\
\-\ age\\:\\ 0\\.02527227173515307\ \(0\)\
\-\ enhancing\\:\\ 0\\.025217140065789213\ \(0\)\
\-\ decreased\\:\\ 0\\.024934560513767592\ \(0\)\
\-\ years\\:\\ 0\\.024675565655428493\ \(0\)\
\-\ evaluation\\:\\ 0\\.02454954770335501\ \(0\)\
\-\ abnormal\\:\\ 0\\.02418445847611443\ \(0\)\
\-\ through\\:\\ 0\\.02396263783476187\ \(0\)\
\-\ include\\:\\ 0\\.023951153995310677\ \(0\)\
\-\ two\\:\\ 0\\.02390540461118413\ \(0\)\
\-\ 10\\:\\ 0\\.023538878511099027\ \(0\)\
\-\ if\\:\\ 0\\.023388955650780564\ \(0\)\
\-\ therapy\\:\\ 0\\.02312891083409106\ \(0\)\
\-\ cell\\:\\ 0\\.023027518029687104\ \(0\)\
\-\ signal\\:\\ 0\\.022819220161797365\ \(0\)\
\-\ patients\\:\\ 0\\.022645445690006035\ \(0\)\
\-\ bilateral\\:\\ 0\\.021634337727330397\ \(0\)\
\-\ associated\\:\\ 0\\.02121722254951124\ \(0\)\
\-\ tumor\\:\\ 0\\.021055520795370618\ \(0\)\
\-\ demonstrate\\:\\ 0\\.020927280064392952\ \(0\)\
\-\ small\\:\\ 0\\.020764707438643164\ \(0\)\
\-\ were\\:\\ 0\\.020750112153635973\ \(0\)\
\-\ present\\:\\ 0\\.020655971577204425\ \(0\)\
\-\ exam\\:\\ 0\\.02026421411147837\ \(0\)\
\-\ may\\:\\ 0\\.020257412358869464\ \(0\)\
\-\ case\\:\\ 0\\.020223501588254606\ \(0\)\
\-\ had\\:\\ 0\\.020056349818478977\ \(0\)\
\-\ female\\:\\ 0\\.019424728327345018\ \(0\)\
\-\ disease\\:\\ 0\\.016897474653471706\ \(0\)\
\-\ be\\:\\ 0\\.01632970476391222\ \(0\)\
